 |
Ric Rumble appointed President and CEO of TSO3October 6, 2008Mr. Rumble has more than 25 years of executive level experiencein the global medical sterilization sector Quebec City, Quebec, Canada, October 6, 2008 – Germain Carrière, the Chairman of the Board of TSO3 Inc. (“TSO3”) (TSX: TOS) is pleased to announce the appointment of Ric Rumble as President and Chief Executive Officer of the Company effective October 14, 2008. Mr. Rumble, who prior to this appointment held the position of President of BERCHTOLD Corporation, has more than 25 years of executive experience in the North American and global medical device industry. “TSO3 is pleased and excited to welcome Ric Rumble to his new position as President and CEO,” said Mr. Carrière. “He has a long and impressive track record in the medical device industry, including delivering significant and sustained revenue and earnings growth, leading successful new commercial strategies and negotiating and integrating large-scale acquisitions. With this background and expertise, I am sure that Ric will bring TSO3 strong and inspired leadership to the benefit of the Company and its shareholders,” said Mr. Carrière. To ensure a smooth leadership transition, Mr. W. Barry McDonald, who has held the position of Interim President and Chief Executive Officer since last May, will stay on with the Company in an advisory role to the new CEO and the Board for a brief period. “I am prepared and enthusiastic to take on this new challenge and to continue the momentum generated from the recently implemented sales, operating and R&D initiatives,” said Mr. Rumble. “I believe that with its innovative and effective sterilization technology, TSO3 has great potential to become a key player in the medical instrument sterilization sector. The market for this technology is significant, and TSO3’s patented ozone sterilization process offers an economical, safe and environmentally friendly alternative to other low temperature sterilization methods widely in use at many hospitals. As President and CEO, I look forward to providing the strategic leadership required to enable TSO3 to achieve its short and long-term growth objectives,” he added. Mr. Rumble holds a Bachelor of Science degree in biology and an Honour’s Bachelor of Science in microbiology and immunology from the University of Western Ontario. For 25 years he has held a variety of management and executive positions at leading medical device manufacturers in Canada and the United States. These previous positions include: President of BERCHTOLD Corporation, Vice President, Sales & Marketing for Strategic Diagnostics Inc., Vice President and General Manager of STERIS Corporation and President and Chief Executive Officer of MediVators Inc. For several years, Mr. Rumble also worked for 3M Company in various management positions, including Global Business Unit Manager, Sterile Processing. About TSO3 TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology with high commercial potential. The Company’s first product, the Sterizone® 125L Ozone Sterilizer, is designed for sterile processing centers in the hospital environment. In contrast to other methods used, the ozone sterilization process developed and patented by TSO3 meets all standards required by the evolution in sterilization needs, which are: significant costs savings, increased safety for patients and hospital staff, and a “green” environmentally safe process. The Company believes that its technology represents an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals. The Sterizone® 125L Ozone Sterilizer is cleared for commercialization by the US Food and Drug Administration and by Health Canada. TSO3 has been in the commercialization phase for this first product since 2006. For more information about TSO3, visit the Company’s Web site at www.tso3.com The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties. The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it. - 30 - Source: TSO3 Inc. Information: Marc Boisjoli CFO (418) 651-0003, ext. 228 mboisjoli@tso3.com Frédéric Tremblay HKDP Tel.: 514 395-0375, ext. 234 |
© 2005-2008 TSO3. All Rights Reserved.
